Abstract:The China Basic Medical Insurance Program was created in 1999 with three objectives: equal accessibility, affordability, and quality. Today, it has become the biggest medical insurance program in the world, covering 95% of China's population. Since 2015, China's healthcare ecosystem has been reshaped by increasing innovation, which has in turn been driven by regulatory reform, enhancement of research and development capability, and capital market development. There has also been improved regulatory efficiency to reduce lags in launching drugs. In 2022, nearly 20% of novel active substances launched globally were from China. China has also risen to become the second biggest contributor to innovation in terms of pipelines. Using a "fast-follow" strategy, many locally developed innovative drugs can compete with products from multinational companies in their quality and pricing. However, China's pharmaceutical and biotechnology industry will continue to face challenges in pricing and reimbursement, as well as a shortened product lifecycle with rapid price erosion. The government has already accelerated the timeline for updating the drug reimbursement list and is willing to create a high-quality medical insurance program. However, some obstacles are hard to overcome, including reimbursement for advanced therapies, limited funding and an increasing burden of disease due to an aging population. This article reviews the trajectory of medical innovation in China, including the challenges. Looking forward, balancing affordability and innovation will be critical for China to continue the trajectory of growth. The article also offers some suggestions for future policy reform, including optimizing reimbursement efficiency with a focus on high-quality solutions, enhancing the value assessment framework, payer repositioning from "value buyer" to "strategic buyer", and developing alternative market access pathways for innovative drugs.

The U.S.Promoting Plan of Innovation Drug Research and Development for Small Business and Its Enlightenment to China

Analyze on the U S Small Business Innovation Policy from the Perspective of Triple Helix Model--comparison Between SBIR and STTR Programs in U S

Equity Financing Potential for Leading R&D of Small and Medium-Sized Biomedical Corporations

STUDY OF THE PROBLEMS EXISTING IN THE PROCESS OF EQUITY FINANCING OF SMALL AND MEDIUM-SIZED INNOVATIVE ENTERPRISES ON THE BASIS OF A QUESTIONNAIRE SURVEY OF INVESTMENT INSTITUTIONS

Shared funding of R&D in small and medium-sized innovative enterprises: the case of Chinese biomedical industry

Research on Capital Policy for Technological Innovation Capability in Chinese Firms

Study on Sustainable China’s Pharmaceutical Innovation Ecosystem

Enlightenment and Reference of SBA in America to Developing of Small Businesses in Western China

Developing an Innovative Materials Enterprise in China: A Nanotechnology Small Business Case Study

Research on the Promotion Effect of Government Subsidies on Innovation of High-Tech Enterprises

How innovation funding leads enterprises to engage in research and development: Small and medium enterprises' perspective

The Research on the Growth of Independent Innovation Entrepreneurial Enterprises and Open Innovation Mechanism Based on Institutional Perspective

Study on the Innovation Model of Governmental Finance for Technology-Oriented Small and Medium-Sized Enterprises

A Conceptual Model For Independent Innovation Of New Drug In China

An Initial Review of Policies for SMEs in the US, Japan and China

Experience and thinking of promoting open source of achievement of state-funded scientific research projects

Interplay of the Amendments to Chinese Scientific and Technological Progress Law and Patent Law

Revolutionizing pharmaceutical innovation: Unveiling the impact of endogenous knowledge spillover in China

The impact of external R&D financing on innovation process from a supply-demand perspective

Balancing medical innovation and affordability in the new healthcare ecosystem in China: Review of pharmaceutical pricing and reimbursement policies

Research on the Development Status and Problems of Scientific and Technological Small and Medium-Sized Enterprises